Masimo Corporation MASI recently announced Sleep Halo, a powerful new feature, for its Masimo W1 Sport advanced health tracking wearable, intended for scientifically based sleep analysis. Sleep Halo is likely to offer overnight sleep data tracking with an unmatched 70,000+ daily measurements of second-by-second continuous health data. Existing Masimo W1 Sport owners will soon be able to update their watch firmware and Masimo Health app to begin their sleep-tracking journey with Sleep Halo. Masimo W1 Sport and Sleep Halo are intended for general health and wellness purposes. More on the Feature Masimo W1 is unique among wearables since it continuously measures the wearer’s SpO2 and PR and provides a truly informed, robust analysis of how one sleeps. The company has benchmarked Sleep Halo with EEG to confirm its stages of sleep are comparable with sleep analysis. With this new scientifically based Sleep Halo, Masimo’s customers are likely to improve their sleep hygiene. Sleep Halo provides useful insights into an individual's sleep quality, including overall timing, duration of sleep stages, periods of rest and waking, episodes of desaturation, and more. It does this by utilizing continuous Masimo pulse oximetry and machine learning. The associated Masimo Health smartphone app displays the nightly analysis along with the Sleep Halo score, an algorithmic measurement of an individual’s overall quality of sleep. The next Masimo Freedom Watch and Band, as well as all subsequent Masimo wearables, are likely to incorporate the Sleep Halo score and sleep analysis feature. More on Masimo’s Patient Monitoring Platforms Masimo’s patient monitoring and connectivity platforms are expandable, customizable patient monitoring and connectivity hubs that integrate an array of technologies, devices and systems to provide multimodal monitoring and connectivity solutions in a single, clinician-centric platform. Masimo’s core measurement technologies are its breakthrough Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo SET pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters, alongside many other modalities, including brain function monitoring and hemodynamic monitoring, among others. Its measurement technologies are available on many types of devices, from bedside hospital monitors, like the Root Patient Monitoring and Connectivity Hub, to various handheld and portable devices, and the tetherless Radius PPG, Radius VSM and Masimo SafetyNet remote patient surveillance solution. The Masimo Hospital Automation Platform facilitates data integration, connectivity and interoperability through solutions like Patient SafetyNet, Iris, iSirona, Replica and UniView to facilitate more efficient clinical workflows and help clinicians provide the best possible care, both in-person and remotely. Leveraging its expertise in hospital-grade technologies, the company has expanded its suite of products intended for use outside the hospital and for home wellness to include Masimo Sleep (a sleep quality solution), the Masimo Radius Tº wireless (a wireless wearable continuous thermometer), Radius PCG (a wireless tetherless capnograph), the Masimo W1 and Masimo Freedom biosensing and smartwatches, among others. Industry Prospects Per a report by Grand View Research, the global telehealth market size was valued at $101.2 billion in 2023 and is expected to witness a growth rate of 24.3% from 2024 to 2030. The market growth is driven by advancements in technology, including improved Internet connectivity and the adoption of smartphones, which contribute to the expansion of telehealth by making healthcare services more accessible and convenient for patients. Another growth factor includes the growing demand for remote healthcare services, mainly due to the COVID pandemic, where the need for virtual consultations and remote monitoring has increased. Notable Developments Recently, Masimo announced the FDA clearance of its Masimo SET-powered MightySat Medical Pulse Oximeter, available over the counter to consumers without a prescription, which has become the first FDA-approved medical fingertip pulse oximeter that customers can directly avail without the need for any formal prescription. Price Performance In the past six months, MASI’s shares have gained 11.2% compared with the industry’s 4.9% growth. The S&P 500 has increased 15% in the same time frame. Zacks Investment Research Image Source: Zacks Investment Research Zacks Rank & Other Stocks to Consider MASI carries a Zacks Rank #2 (Buy), at present. Some other top-ranked stocks in the broader medical space that have announced quarterly results are DaVita DVA, Ecolab ECL and Universal Health Services UHS. DaVita, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. DaVita’s shares have gained 44% compared with the industry’s 20.4% growth in the past year. Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%. Ecolab’s shares have gained 33.8% against the industry’s 9.3% decline in the past year. Universal Health Services has an Earnings ESP of +2.91% and a Zacks Rank of 2, at present. UHS has an estimated earnings growth rate of 30.5% for 2024. UHS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.12%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ecolab Inc. (ECL):Free Stock Analysis Report Universal Health Services, Inc. (UHS):Free Stock Analysis Report DaVita Inc. (DVA):Free Stock Analysis Report Masimo Corporation (MASI):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Masimo's (MASI) WI Sport Wearable Gets a New Powerful Feature
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...